The V3 Loops of the HIV-1 and HTV-2 Surface Glycoproteins Contain Proteolytic Cleavage Sites: A Possible Function in Viral Fusion?-Reference-Cited by-同舟云学术

The V3 Loops of the HIV-1 and HTV-2 Surface Glycoproteins Contain Proteolytic Cleavage Sites: A Possible Function in Viral Fusion?

Published:1991-01 Issue:1 Volume:7 Page:3-16
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

CLEMENTS GARY J.,PRICE-JONES MOLLY J.,STEPHENS PAUL E.,SUTTON CHRISTOPHER,SCHULZ THOMAS F.,CLAPHAM PAUL R.,McKEATING JANE A.,McCLURE MYRA O.,THOMSON SUSAN,MARSH MARK,KAY JOHN,WEISS ROBIN A.,MOORE JOHN P.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.1991.7.3

Reference67 articles.

1. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

2. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

3. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain

4. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor

5. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane

Cited by 269 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env;Vaccines;2021-03-10

2. Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens;PLOS ONE;2020-05-29

3. Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells;Biotechnology and Bioengineering;2019-06-10

4. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies;PLOS ONE;2018-04-24

5. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential;European Journal of Medicinal Chemistry;2018-04